Already, biotechnology companies are being more selective about what compounds they invest in and which studies theyll undertake, said Bruce Chabner, a professor of medicine at Harvard Medical School in Boston. The American Society of Clinical Oncology, which starts May 29, may give at least 30 companies with no marketed drugs their last best chance to seek deals with larger drugmakers eager to expand in the $78 billion cancer market, according to industry executives, analysts and investors interviewed this month.
Failing to secure a development partnership, or - - - - >

If a deal goes through, the worlds biggest drugmaker would see its revenue jump 50 percent and its profit climb, would vault into a premier position in two areas its been coveting - biotech drugs and vaccines - and could slash costs with another round of job cuts in areas with significant overlap, from administration to research.
What are the chances a deal will close?
“Id say maybe better than 50-50,” said analyst Les Funtleyder of Miller Tabak & Co.
Analysts say Pfizer, the maker of impotence drug Viagra and overactive bladder treatment Detrol, needs to do something dramatic to compensate for a - - - - >